IGF-1 plays a key role in muscle hypertrophy, repair, and vascularization. Our AAV9-based therapy delivers IGF-1 selectively to skeletal muscle via systemic injection—activating local growth without elevating systemic hormone levels. In early human testing, visible hypertrophy occurred within 7 days, with no heart or liver uptake and minimal side effects.

Fentanyl and its analogs are among the most potent synthetic opioids ever developed, posing both public health and battlefield chemical threats. Our long-acting antibody neutralizes fentanyl molecules in the bloodstream before they can bind to CNS receptors. It has demonstrated protection against carfentanil at 10x lethal dose equivalents in vivo.

Peptide YY₃₋₃₆ acts on the Y2 receptor to signal satiety, but suffers from poor stability and off-target effects. Our novel PYY analog is optimized for buccal (oral mucosal) delivery, engineered from canonical amino acids for Y2 selectivity and resistance to enzymatic degradation. It avoids immunogenicity and can be produced in GRAS-certified microbial hosts.